Quote this publication Share Print

DELPRIM (trimethoprim), antibiotic

INFECTIOUS DISEASE - New medicinal product
Opinions on drugs - Posted on Oct 13 2016

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment of acute uncomplicated cystitis in women and adolescents.

  • DELPRIM has Marketing Authorisation in the treatment of acute uncomplicated cystitis in women and adolescents, at the dosage of 300 mg/day for 3 days.
  • The efficacy of trimethoprim, although poorly evaluated at this dosage, seems to be similar to that of alternative medicinal products. Data in adolescents are limited.
  • DELPRIM is not indicated for use in empirical therapy.
  • It is a new treatment option in case of documented infection with ESBL-producing E. coli, as an alternative to trimethoprim-sulfamethoxazole combination therapy and to a fluoroquinolone, prescription of which should be considered in case of more severe infections.

Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments